JAK 1 and 2 inhibitor superior to adalimumab in treatment of rheumatoid arthritis: The RA-BEAM trial
1. Baricitinib, an oral, once-daily inhibitor of JAK1 and JAK2, has shown promise in the treatment of rheumatoid arthritis (RA)....
Shaidah attended York University for her undergraduate degree and majored in Health Sciences with a specialization in cellular physiology. She then completed her Master of Science degree in Nutritional Sciences at the University of Toronto in 2011. After working in the research field for two years, she started studying medicine at the University of Toronto. In 2017, she completed her training and started working at Queen's University as a Resident in General Surgery.
1. Baricitinib, an oral, once-daily inhibitor of JAK1 and JAK2, has shown promise in the treatment of rheumatoid arthritis (RA)....
1. Prophylactic low-molecular-weight heparin (LMWH) for 8 days post knee arthroscopy demonstrated no change in the incidence of venous thromboembolism...
1. Centrifugal-flow left ventricular assist devices (LVAD) were found to be noninferior to traditional axis-flow devices for the treatment of...
1. The addition of biclutamide (antiandrogen) to radiation therapy for recurrent prostate cancer improved overall survival compared to radiation alone....
1. Patients with sickle cell disease treated with high-dose crizanlizumab experienced lower annualized rates of sickle cell crisis compared to...
1. Patients with multiple sclerosis (MS) treated with ocrelizumab experienced lower annualized relapse rates compared to those treated with interferon...
1. A significant decrease in the rate of clinical and MRI progression was observed for Primary progressive multiple sclerosis (PPMS)...
1. In this study, no significant intergroup differences between amitriptyline, topiramate and placebo for reduction in total number of headache...
1. 177Lu-Dotatate, a radiolabeled somatostatin analogue, was associated with increased progression-free survival and decreased overall mortality compared to standard therapy...
1. Tranexamic acid demonstrated a significantly lower risk of bleeding complications and transfusion requirements compared to placebo in patients undergoing...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.